Pfizer Inc (PFE)
26.32
+0.06
(+0.23%)
USD |
NYSE |
Apr 23, 16:00
26.34
+0.02
(+0.08%)
After-Hours: 18:00
Pfizer Revenue (Annual): 58.50B for Dec. 31, 2023
Revenue (Annual) Chart
Historical Revenue (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 58.50B |
| December 31, 2022 | 100.33B |
| December 31, 2021 | 81.29B |
| December 31, 2020 | 41.65B |
| December 31, 2019 | 40.90B |
| December 31, 2018 | 40.82B |
| December 31, 2017 | 52.55B |
| December 31, 2016 | 52.82B |
| December 31, 2015 | 48.85B |
| December 31, 2014 | 49.60B |
| December 31, 2013 | 51.58B |
| December 31, 2012 | 54.66B |
| December 31, 2011 | 61.04B |
| December 31, 2010 | 65.16B |
| December 31, 2009 | 50.01B |
| December 31, 2008 | 48.30B |
| December 31, 2007 | 48.42B |
| December 31, 2006 | 48.37B |
| December 31, 2005 | 47.40B |
| December 31, 2004 | 48.99B |
| Date | Value |
|---|---|
| December 31, 2003 | 44.74B |
| December 31, 2002 | 32.29B |
| December 31, 2001 | 29.02B |
| December 31, 2000 | 29.36B |
| December 31, 1999 | 27.38B |
| December 31, 1998 | 23.23B |
| December 31, 1997 | 11.06B |
| December 31, 1996 | 9.864B |
| December 31, 1995 | 10.02B |
| December 31, 1994 | 8.281B |
| December 31, 1993 | 7.478B |
| December 31, 1992 | 7.230B |
| December 31, 1991 | 6.95B |
| December 31, 1990 | 6.406B |
| December 31, 1989 | 5.672B |
| December 31, 1988 | 5.385B |
| December 31, 1987 | 4.920B |
| December 31, 1986 | 4.476B |
| December 31, 1985 | 4.024B |
| December 31, 1984 | 3.854B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Annual) Range, Past 5 Years
40.90B
Minimum
2019
100.33B
Maximum
2022
64.53B
Average
58.50B
Median
2023
Revenue (Annual) Benchmarks
| Amgen Inc | 28.19B |
| Gilead Sciences Inc | 27.12B |
| Johnson & Johnson | 85.16B |
| Viking Therapeutics Inc | -- |
| Moderna Inc | 6.754B |